Background: Biochemical recurrence (BCR) after definitive radiotherapy (RT) in localized prostate cancer (PC) is a clinically relevant event that impacts long-term management and prognosis. However, the prognostic value of certain biopsy-derived pathological parameters remains underexplored in RT-treated cohorts. Methods: We retrospectively analyzed 444 patients with localized PC treated with external beam radiotherapy (with or without androgen deprivation therapy) between 2013 and 2019. Clinical, radiological, and detailed histopathological data, including Gleason score, perineural invasion, and the number and proportion of positive biopsy cores—were collected. Logistic regression models were used to identify predictors of BCR. Results: After a median follow-up of 72 months, 11.7% of patients developed BCR. In multivariable analysis, higher PSA at diagnosis (p = 0.05), higher Gleason score (ISUP ≥ 4; p = 0.036), and greater tumor burden in biopsy cores—quantified as both the number and proportion of positive cores per lobe and overall (p < 0.05)—were independently associated with BCR. Perineural invasion showed a univariable association (p = 0.036), though it did not remain significant after adjustment. Overall, 19.2% (10/52) of recurrences were diagnosed beyond five years post-treatment, underscoring the need for prolonged follow-up. Conclusions: PSA at diagnosis, the extent of tumor involvement in diagnostic biopsies, and ISUP grade group ≥ 4 (Gleason score ≥ 8) were identified as independent predictors of biochemical recurrence after RT in localized prostate cancer. Lower Gleason categories and perineural invasion showed only a trend toward significance in the multivariable analysis, suggesting that their predictive effect may be attenuated by other covariates.
Introduction: ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone-releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 nmol/L) and were moderately correlated (Spearman ρ = 0.43, p = 0.002; Pearson r = 0.51, p < 0.001). No baseline clinical, histologic, or biochemical variables reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p = 0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with more than half of cases achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories.
22 April 2025 in Clinical and Translational Oncology
Introduction : ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone–releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 ng/mL) and were moderately correlated (Spearman ρ=0.43, p=0.002; Pearson r=0.51, p< 0.001). No baseline clinical, histologic, or biochemical variable reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p=0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with most patients achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs antagonist trajectories.
Prognostic Factors Associated with Biochemical Relapse after Radiotherapy in Localized Prostate Cancer: A Retrospective Cohort Study Background: Biochemical recurrence (BCR) after definitive radiotherapy (RT) in localized prostate cancer (PC) is a clinically relevant event that impacts long-term management and prognosis. However, the prognostic value of certain biopsy-derived pathological parameters remains underexplored in RT-treated cohorts. Methods: We retrospectively analyzed 444 patients with localized PC treated with external beam radiotherapy (with or without androgen deprivation therapy) between 2013 and 2019. Clinical, radiological, and detailed histopathological data, including Gleason score, perineural invasion, and the number and proportion of positive biopsy cores—were collected. Logistic regression models were used to identify predictors of BCR. Results: After a median follow-up of 72 months, 11.7% of patients developed BCR. In multivariable analysis, higher PSA at diagnosis (p = 0.05), higher Gleason score (ISUP ≥4; p = 0.036), and greater tumor burden in biopsy cores—quantified as both number and proportion of positive cores per lobe and overall (p < 0.05)—were independently associated with BCR. Perineural invasion showed a univariable association (p = 0.036), though it did not remain significant after adjustment. Notably, nearly one-fourth of recurrences occurred beyond five years post-treatment, underscoring the need for prolonged follow-up. Conclusions: PSA level, Gleason grade, and extent of tumor involvement in diagnostic biopsies are strong, independent predictors of BCR following RT. These findings support the incorporation of detailed biopsy metrics into routine risk stratification to inform personalized surveillance strategies.